Cingulate Inc. (CING )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol CING
- Company Cingulate Inc.
- Price $11.66
- Changes Percentage 8.77
- Change 0.94
- Day Low $10.4
- Day High $11.89
- Year High $7.92
- Year Low $3.2
- Market Cap $44,119,519
- Price Avg 50 EMA (D) $5.8
- Price Avg 200 EMA (D) $4.53
- Exchange NASDAQ
- Volume 489,222
- Average Volume 303,208
- Open $11.32
- Previous Close $10.72
- EPS -2.77
- PE -2.84
- Earnings Announcement 2026-03-09 12:00:00
- Shares Outstanding $5,606,038
Company brief: CINGULATE INC. (CING )
- Healthcare
- Biotechnology
- Dr. Shane J. Schaffer Pharm.D., PharmD
- https://www.cingulate.com
- US
- N/A
- 12-08-2021
- US17248W2044
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
CING Corporation News
Why did Cingulate stock skyrocket today?
invezz.com -- Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release Tab...